Evidence-based guideline: Treatment of parenchymal neurocysticercosis: Report of the guideline development subcommittee of the American Academy of Neurology

Ruth Ann Baird, Sam Wiebe, Joseph R. Zunt, John J. Halperin, Gary Gronseth, Karen Roos

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Objective: To review the evidence base for different treatment strategies in intraparenchymal neurocysticercosis in adults and children. Method: A literature search of Medline, EMBASE, LILACS, and the Cochrane Database from 1980 to 2008, updated in 2012, resulted in the identification of 10 Class I or Class II trials of cysticidal drugs administered with or without corticosteroids in the treatment of neurocysticercosis. Results: The available data demonstrate that albendazole therapy, administered with or without corticosteroids, is probably effective in decreasing both long-term seizure frequency and the number of cysts demonstrable radiologically in adults and children with neurocysticercosis, and is well-tolerated. There is insufficient information to assess the efficacy of praziquantel. Recommendations: Albendazole plus either dexamethasone or prednisolone should be considered for adults and children with neurocysticercosis, both to decrease the number of active lesions on brain imaging studies (Level B) and to reduce long-term seizure frequency (Level B). The evidence is insufficient to support or refute the use of steroid treatment alone in patients with intraparenchymal neurocysticercosis (Level U).

Original languageEnglish
Pages (from-to)1424-1429
Number of pages6
JournalNeurology
Volume80
Issue number15
DOIs
StatePublished - Apr 9 2013

Fingerprint

Neurocysticercosis
Guidelines
Albendazole
Adrenal Cortex Hormones
Seizures
Therapeutics
Praziquantel
Prednisolone
Neuroimaging
Dexamethasone
Cysts
Steroids
Databases
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Evidence-based guideline : Treatment of parenchymal neurocysticercosis: Report of the guideline development subcommittee of the American Academy of Neurology. / Baird, Ruth Ann; Wiebe, Sam; Zunt, Joseph R.; Halperin, John J.; Gronseth, Gary; Roos, Karen.

In: Neurology, Vol. 80, No. 15, 09.04.2013, p. 1424-1429.

Research output: Contribution to journalArticle

Baird, Ruth Ann ; Wiebe, Sam ; Zunt, Joseph R. ; Halperin, John J. ; Gronseth, Gary ; Roos, Karen. / Evidence-based guideline : Treatment of parenchymal neurocysticercosis: Report of the guideline development subcommittee of the American Academy of Neurology. In: Neurology. 2013 ; Vol. 80, No. 15. pp. 1424-1429.
@article{a8310899f30444179640bcb49b75cc8e,
title = "Evidence-based guideline: Treatment of parenchymal neurocysticercosis: Report of the guideline development subcommittee of the American Academy of Neurology",
abstract = "Objective: To review the evidence base for different treatment strategies in intraparenchymal neurocysticercosis in adults and children. Method: A literature search of Medline, EMBASE, LILACS, and the Cochrane Database from 1980 to 2008, updated in 2012, resulted in the identification of 10 Class I or Class II trials of cysticidal drugs administered with or without corticosteroids in the treatment of neurocysticercosis. Results: The available data demonstrate that albendazole therapy, administered with or without corticosteroids, is probably effective in decreasing both long-term seizure frequency and the number of cysts demonstrable radiologically in adults and children with neurocysticercosis, and is well-tolerated. There is insufficient information to assess the efficacy of praziquantel. Recommendations: Albendazole plus either dexamethasone or prednisolone should be considered for adults and children with neurocysticercosis, both to decrease the number of active lesions on brain imaging studies (Level B) and to reduce long-term seizure frequency (Level B). The evidence is insufficient to support or refute the use of steroid treatment alone in patients with intraparenchymal neurocysticercosis (Level U).",
author = "Baird, {Ruth Ann} and Sam Wiebe and Zunt, {Joseph R.} and Halperin, {John J.} and Gary Gronseth and Karen Roos",
year = "2013",
month = "4",
day = "9",
doi = "10.1212/WNL.0b013e31828c2f3e",
language = "English",
volume = "80",
pages = "1424--1429",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Evidence-based guideline

T2 - Treatment of parenchymal neurocysticercosis: Report of the guideline development subcommittee of the American Academy of Neurology

AU - Baird, Ruth Ann

AU - Wiebe, Sam

AU - Zunt, Joseph R.

AU - Halperin, John J.

AU - Gronseth, Gary

AU - Roos, Karen

PY - 2013/4/9

Y1 - 2013/4/9

N2 - Objective: To review the evidence base for different treatment strategies in intraparenchymal neurocysticercosis in adults and children. Method: A literature search of Medline, EMBASE, LILACS, and the Cochrane Database from 1980 to 2008, updated in 2012, resulted in the identification of 10 Class I or Class II trials of cysticidal drugs administered with or without corticosteroids in the treatment of neurocysticercosis. Results: The available data demonstrate that albendazole therapy, administered with or without corticosteroids, is probably effective in decreasing both long-term seizure frequency and the number of cysts demonstrable radiologically in adults and children with neurocysticercosis, and is well-tolerated. There is insufficient information to assess the efficacy of praziquantel. Recommendations: Albendazole plus either dexamethasone or prednisolone should be considered for adults and children with neurocysticercosis, both to decrease the number of active lesions on brain imaging studies (Level B) and to reduce long-term seizure frequency (Level B). The evidence is insufficient to support or refute the use of steroid treatment alone in patients with intraparenchymal neurocysticercosis (Level U).

AB - Objective: To review the evidence base for different treatment strategies in intraparenchymal neurocysticercosis in adults and children. Method: A literature search of Medline, EMBASE, LILACS, and the Cochrane Database from 1980 to 2008, updated in 2012, resulted in the identification of 10 Class I or Class II trials of cysticidal drugs administered with or without corticosteroids in the treatment of neurocysticercosis. Results: The available data demonstrate that albendazole therapy, administered with or without corticosteroids, is probably effective in decreasing both long-term seizure frequency and the number of cysts demonstrable radiologically in adults and children with neurocysticercosis, and is well-tolerated. There is insufficient information to assess the efficacy of praziquantel. Recommendations: Albendazole plus either dexamethasone or prednisolone should be considered for adults and children with neurocysticercosis, both to decrease the number of active lesions on brain imaging studies (Level B) and to reduce long-term seizure frequency (Level B). The evidence is insufficient to support or refute the use of steroid treatment alone in patients with intraparenchymal neurocysticercosis (Level U).

UR - http://www.scopus.com/inward/record.url?scp=84876279118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876279118&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31828c2f3e

DO - 10.1212/WNL.0b013e31828c2f3e

M3 - Article

C2 - 23568997

AN - SCOPUS:84876279118

VL - 80

SP - 1424

EP - 1429

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 15

ER -